Furthermore, SLAMF7 is known to be a regulator of NK cell function, and in vitro studies have shown that elotuzumab binding to SLAMF7 on NK cells directly activates them, enhancing their cytotoxic activity against myeloma cells. This evidence concerns the gene SLAMF7 and plasma cell myeloma.